Rebirth of Aducanumab : Alzheimer’s Disease business in the mist
Targeting the $1.33 trillion-worth market of Alzheimer’s Disease (AD), Biogen wants to take a step ahead. Joint with Eisai, the two pharma giants filed a second request of regulatory approval for the new drug, aducanumab, on Oct. 22, 2019, arguing for its effectiveness. The compound was developed for AD patients, undertaking the hypothesis that the…